Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives &
Strategic Plans
Generex Biotechnology Corporation (www.generex.com)
(OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote)
today announced the following access information for its investor conference call, to be hosted by President & Chief Executive
Officer Joseph Moscato, and his management team Monday, December 3, 2018, at 9:00 a.m. Eastern time:
Domestic US/Canada – 1-(866) 831-8711
Direct Toll / International - 1-(203) 518-9865
Conference ID - 91472
WEB MEETING:
https://www.conferencecalling.com/meeting/75419884
The purpose of the conference call is to provide Company stockholders and other interested parties with an update in respect of
the Company’s initiatives and strategic plans.
About Generex Biotechnology Corporation
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical
devices, and pharmaceutical development.
The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and
additional health-related services to greatly improve the patient experience in receiving care.
On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including
private practice and hospital, allowing doctors to devote more time to patient care.
Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus
in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary
buccal administration of insulin.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with
any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid
placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
800-391-6755 Extension 222
investor@generex.com
Russo Partners
Investor / Media Contacts:
Alex Fudukidis
(646) 942-5632
alex.fudukidis@russopartnersllc.com
Caroline Cunningham
(212) 845-4292
Caroline.Cunningham@russopartnersllc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005074/en/